10-Q: Avenue Therapeutics Reports Q2 2025 Results

Avenue Therapeutics reports Q2 2025 results, including revenue from AnnJi license termination and a net income attributable to Avenue.

Summary

• Avenue Therapeutics reported a net income attributable to Avenue of $335,000 for the three months ended June 30, 2025, compared to a net loss of $2.692 million for the same period in 2024.
• For the six months ended June 30, 2025, the company reported a net loss attributable to Avenue of $1.517 million, compared to a net loss of $7.032 million for the same period in 2024.
• The company generated $1.4 million in revenue related to the AnnJi license termination and program transfer during the six months ended June 30, 2025.
• Research and development expenses decreased to $0.6 million for the six months ended June 30, 2025, from $3.8 million for the same period in 2024, primarily due to the termination of the AnnJi license agreement.
• General and administrative expenses decreased to $2.4 million for the six months ended June 30, 2025, from $2.8 million for the same period in 2024.
• As of June 30, 2025, the company had $3.3 million in cash and cash equivalents and an accumulated deficit of $104.1 million.
• The company's common stock was delisted from Nasdaq on July 18, 2025, and is now trading on the OTCID market under the symbol ATXI.

Sentiment

Score: 3

Explanation: The filing contains both positive and negative aspects. The revenue from the AnnJi license termination and the decrease in net loss, R&D expenses, and G&A expenses are positive. However, the accumulated deficit, the delisting from Nasdaq, and the substantial doubt about the company's ability to continue as a going concern are negative. Overall, the sentiment is slightly negative.

Positives

• The company generated $1.4 million in revenue related to the AnnJi license termination and program transfer during the six months ended June 30, 2025.
• Net loss attributable to Avenue decreased to $1.517 million for the six months ended June 30, 2025, from $7.032 million for the same period in 2024.
• Research and development expenses decreased to $0.6 million for the six months ended June 30, 2025, from $3.8 million for the same period in 2024.
• General and administrative expenses decreased to $2.4 million for the six months ended June 30, 2025, from $2.8 million for the same period in 2024.

Negatives

• The company had an accumulated deficit of $104.1 million as of June 30, 2025.
• The company's common stock was delisted from Nasdaq on July 18, 2025.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company needs to secure additional funds through equity or debt offerings.

Risks

• The company currently has no drug products for sale and its success is dependent on its product candidates receiving regulatory approval and being successfully commercialized.
• Serious adverse or unacceptable side effects could be identified during the development of current or future product candidates.
• The company may not be able to successfully develop, partner, or commercialize any of its current or future product candidates including IV tramadol and BAER-101.
• The company needs substantial additional funding, which may not be available on acceptable terms, or at all.
• The company relies on third parties for several aspects of its operations.
• The company relies on clinical data and results obtained by third parties that could ultimately prove to be inaccurate, unreliable, or unacceptable to regulatory authorities.
• The company may not receive regulatory approval for any or all of its product candidates, or that such approval may be significantly delayed due to scientific or regulatory reasons.
• Even if one or more of the company's product candidates receives regulatory approval, they will remain subject to substantial regulatory scrutiny.
• The government or third-party payors may fail to provide adequate coverage and payment rates for the company's product candidates or any future products.
• The company may be exposed to potential product liability claims.
• The company may be unable to maintain sufficient patent protection for its technology and products.
• The company may be unable to maintain compliance with the obligations under its intellectual property licenses and funding arrangements with third parties.
• Fortress Biotech, Inc. controls a majority of the voting power of the company's outstanding capital stock and has rights to receive significant share grants annually.
• The OTCID Market is a thinly traded market lacking in liquidity, and subject to volatility.
• The company's common stock may be considered a penny stock and, therefore, may be subject to certain rules that make it difficult for brokers, dealers, or investors to sell the shares.

Future Outlook

The company expects to continue to incur research and development costs and general and administrative costs and incur operating losses for at least the next several years as it continues the development of its product candidates. The company intends to obtain additional capital through the sale of debt or equity securities or other arrangements to fund its operations, research and development activity or regulatory approval activity.

Industry Context

Avenue Therapeutics is operating in the specialty pharmaceutical industry, which is characterized by high research and development costs, regulatory hurdles, and competition from other companies developing therapies for neurologic diseases. The company's focus on IV tramadol and BAER-101 aligns with the industry trend of developing targeted therapies for specific patient populations.

Comparison to Industry Standards

• Given the delisting from NASDAQ and the going concern doubts, Avenue Therapeutics is underperforming compared to industry peers.
• Companies like Pacira BioSciences (PCRX) and Heron Therapeutics (HRTX) focus on post-operative pain management but have approved products and established revenue streams, unlike Avenue.
• In the epilepsy and panic disorder space, companies like Sage Therapeutics (SAGE) and Marinus Pharmaceuticals (MRNS) are further along in clinical development and commercialization.
• Avenue's reliance on Fortress Biotech for management services and financing is similar to other small-cap biopharma companies but also introduces potential conflicts of interest.

Related Party Transactions

• The company has a Management Services Agreement with Fortress Biotech, Inc. Expenses related to the MSA are recorded 50% in research and development expenses and 50% in general and administrative expenses.
• The company issued 22,476 shares of common stock to Fortress as the Annual Stock Dividend on January 2, 2025, representing 2.5% of the fully-diluted outstanding equity of the Company on December 31, 2024.
• The Founders Agreement and Management Services Agreement that had previously been existing between Fortress and Baergic were assigned to Avenue, such that they now exist between Avenue and Baergic.

Stakeholder Impact

• Shareholders: The delisting from Nasdaq may negatively impact the liquidity and market price of the company's common stock and could make it more difficult for shareholders to dispose of their holdings. The need for additional financing may dilute existing stockholders.
• Employees: The company's ability to continue as a going concern and secure additional funding will impact its ability to retain and attract employees.
• Customers: The company's ability to develop and commercialize its product candidates will impact its ability to provide therapies for patients with neurologic diseases.
• Creditors: The company's ability to secure additional financing will impact its ability to meet its debt obligations.

Next Steps

• The company will continue to develop and attempt to gain regulatory approval for its existing product candidates.
• The company will explore strategic alternatives for its Baergic subsidiary.
• The company will seek opportunities to license or acquire additional products.
• The company will analyze various alternatives for enhancing its capital structure, including potentially obtaining lines of credit, debt or equity financings.

Key Dates

Recommendation

Given the delisting from NASDAQ, the going concern doubts, and the need for additional financing, a sell recommendation is appropriate. The company faces significant challenges in the near term, and the risks outweigh the potential rewards.

Keywords

Avenue Therapeutics, ATXI, IV tramadol, BAER-101, AnnJi, License Termination, Q2 2025, Financial Results, Neurologic Diseases, Pharmaceutical